Cat. #161960
VCaP 11 [ENZA A] CRPC Cell line
Cat. #: 161960
Availability: 8-10 weeks
Organism: Human
Tissue: Prostate
Disease: Cancer
Model: Tumour Cell Line
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Wytske van Weerden
Institute: Erasmus University Medical Centre
Primary Citation: Moll JM et al. 2022. Front. Oncol. Jun 13,12:877613. PMID: 35769712
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: VCaP 11 [ENZA A] CRPC Cell line
- Research fields: Cancer
- Parental cell: VCaP
- Organism: Human
- Tissue: Prostate
- Disease: Cancer
- Model: Tumour Cell Line
- Model description: CRPC model
- Receptors of note: Androgen receptor
- Description: CRPC VCaP cell lines (15 sublines made resistant to common antiandrogens through long-term passaging) - Enzalutamide A. VCaP Enzalutamide cells were generated by long-term culturing of VCaP cells in androgen depleted media with Enzalutamide, an AR antagonist. These cell lines can be used to study the role of AR signalling and mechanisms of resistance to androgen deprivation therapy and AR targeting agents in CRPC. This cell line is subclone A.
- Application: Tumour Modelling
Applications
- Application: Tumour Modelling
Handling
- Growth medium: RPMI1640 + 10% DCC-FCS + 1 uM ENZ
- Storage conditions: liquid N2
- Cultured in antibiotics: 1% Penicillin/Streptomycin
References
- Moll JM et al. 2022. Front. Oncol. Jun 13,12:877613. PMID: 35769723
